Xponance’s Spyre Therapeutics SYRE Stock Holding History

Xponance’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$647K	Buy	7,291 +846	+13%	+$61.7K	﹤0.01%	978
2026 Q1	$325K	Buy	+6,445	New	+$243K	﹤0.01%	1219

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Xponance's SYRE Position: Q2 2026 in Review

Xponance increased its Spyre Therapeutics (SYRE) stake by 13% in Q2 2026, buying an estimated $61.7K and bringing the position to 7,291 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Xponance first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Xponance held 7,291 shares of Spyre Therapeutics worth $647K as of Q2 2026.
Xponance bought 846 Spyre Therapeutics shares in Q2 2026, an estimated $61.7K.
Spyre Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #978 holding.
Xponance first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.